⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 3, 2024Frontiers in OncologyOpen Access

Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases

Zeyu Liu Ming Li Ziyi Zhao Aina Liu Ping Sun

View Full Paper

Ask AI

Bookmark

Share

Abstract

The anti-angiogenic agent anlotinib offers a new treatment option for triple-negative breast cancer (TNBC) patients with brain metastases. This study aimed to evaluate the efficacy and safety of anlotinib in the treatment of TNBC patients with brain metastases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee1e2b3180350efb9f5 https://doi.org/10.3389/fonc.2024.1439984

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer.2024
2Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial2024 · 8 citations
3Efficacy and safety of anlotinib in the treatment of brain metastases from non-small cell lung cancer: a systematic review and meta-analysis2025
4Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases2024 · 2 citations
5Efficacy and Safety of Anlotinib‐Based Regimens in Metastatic Breast Cancer: A Multicenter Real‐World Study2025